• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RERT:一种预测子宫内膜癌患者宫外疾病的新回归树方法。

RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients.

机构信息

Department of Molecular and Translational Medicine, Unit of Biostatistics, University of Brescia, Brescia, Italy.

"Angelo Nocivelli" Institute of Molecular Medicine, Division of Obstetrics and Gynecology, University of Brescia, Brescia, Italy.

出版信息

Sci Rep. 2017 Sep 5;7(1):10528. doi: 10.1038/s41598-017-11104-4.

DOI:10.1038/s41598-017-11104-4
PMID:28874808
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5585365/
Abstract

Some aspects of endometrial cancer (EC) preoperative work-up are still controversial, and debatable are the roles played by lymphadenectomy and radical surgery. Proper preoperative EC staging can help design a tailored surgical treatment, and this study aims to propose a new algorithm able to predict extrauterine disease diffusion. 293 EC patients were consecutively enrolled, and age, BMI, children's number, menopausal status, contraception, hormone replacement therapy, hypertension, histological grading, clinical stage, and serum HE4 and CA125 values were preoperatively evaluated. In order to identify before surgery the most important variables able to classify EC patients based on FIGO stage, we adopted a new statistical approach consisting of two-steps: 1) Random Forest with its relative variable importance; 2) a novel algorithm able to select the most representative Regression Tree (RERT) from an ensemble method. RERT, built on the above mentioned variables, provided a sensitivity, specificity, NPV and PPV of 90%, 76%, 94% and 65% respectively, in predicting FIGO stage > I. Notably, RERT outperformed the prediction ability of HE4, CA125, Logistic Regression and single cross-validated Regression Tree. Such algorithm has great potential, since it better identifies the true early-stage patients, thus providing concrete support in the decisional process about therapeutic options to be performed.

摘要

子宫内膜癌(EC)术前检查的某些方面仍存在争议,淋巴结切除术和根治性手术的作用也存在争议。正确的术前 EC 分期有助于设计个体化的手术治疗,本研究旨在提出一种新的算法,以预测宫外疾病的扩散。连续纳入 293 例 EC 患者,术前评估年龄、BMI、儿童人数、绝经状态、避孕、激素替代疗法、高血压、组织学分级、临床分期以及血清 HE4 和 CA125 值。为了在术前识别出能够基于 FIGO 分期对 EC 患者进行分类的最重要变量,我们采用了一种新的统计方法,包括两步:1)随机森林及其相对重要性变量;2)一种能够从集成方法中选择最具代表性的回归树(RERT)的新算法。基于上述变量构建的 RERT 在预测 FIGO 分期 > I 方面的敏感性、特异性、NPV 和 PPV 分别为 90%、76%、94%和 65%。值得注意的是,RERT 的预测能力优于 HE4、CA125、Logistic 回归和单交叉验证回归树。该算法具有很大的潜力,因为它可以更好地识别真正的早期患者,从而为治疗方案的决策过程提供具体支持。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/99c620819ac0/41598_2017_11104_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/a8a0695c4c80/41598_2017_11104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/36ca2981733b/41598_2017_11104_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/6b08c8cf6f97/41598_2017_11104_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/99c620819ac0/41598_2017_11104_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/a8a0695c4c80/41598_2017_11104_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/36ca2981733b/41598_2017_11104_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/6b08c8cf6f97/41598_2017_11104_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e418/5585365/99c620819ac0/41598_2017_11104_Fig4_HTML.jpg

相似文献

1
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients.RERT:一种预测子宫内膜癌患者宫外疾病的新回归树方法。
Sci Rep. 2017 Sep 5;7(1):10528. doi: 10.1038/s41598-017-11104-4.
2
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。
Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.
3
Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.术前 ROMA 评分与上皮性卵巢癌患者临床分期的相关性。
Clin Transl Oncol. 2017 Oct;19(10):1260-1267. doi: 10.1007/s12094-017-1664-8. Epub 2017 Apr 25.
4
Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.血清人附睾蛋白4在预测上皮性卵巢癌手术预后较差方面优于癌抗原125。
Tumour Biol. 2016 Nov;37(11):14765-14772. doi: 10.1007/s13277-016-5335-0. Epub 2016 Sep 15.
5
Preoperative serum CA125: a useful marker for surgical management of endometrial cancer.术前血清CA125:子宫内膜癌手术治疗的有用标志物。
BMC Cancer. 2015 May 12;15:396. doi: 10.1186/s12885-015-1260-7.
6
Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.肿瘤标志物HE4作为子宫内膜癌预后因素的效用:一项单中心对照研究。
Tumour Biol. 2015 Jun;36(6):4151-6. doi: 10.1007/s13277-015-3049-3. Epub 2015 Jan 11.
7
Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management.术前了解生物标志物人附睾蛋白4在早期子宫内膜癌手术治疗中的重要性。
Anticancer Res. 2017 May;37(5):2697-2702. doi: 10.21873/anticanres.11619.
8
The role of HE4 and CA125 in differentiation between malignant and non-malignant endometrial pathologies.人附睾蛋白4(HE4)和癌抗原125(CA125)在鉴别恶性和非恶性子宫内膜病变中的作用。
Ginekol Pol. 2016;87(12):781-786. doi: 10.5603/GP.2016.0088.
9
The prognostic role of preoperative serum CA125 levels in patients with advanced endometrial carcinoma.术前血清CA125水平在晚期子宫内膜癌患者中的预后作用。
Cancer Biomark. 2017 Aug 23;20(2):135-141. doi: 10.3233/CBM-160529.
10
HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).HE4 和 CA125 水平在子宫内膜癌患者术前评估中的应用:一项前瞻性多中心研究(ENDOMET)。
Acta Obstet Gynecol Scand. 2013 Nov;92(11):1313-22. doi: 10.1111/aogs.12235.

引用本文的文献

1
Mitochondrial Dysfunction in Peripheral Blood Mononuclear Cells as Novel Diagnostic Tools for Non-Alcoholic Fatty Liver Disease: Visualizing Relationships with Known and Potential Disease Biomarkers.外周血单个核细胞中的线粒体功能障碍作为非酒精性脂肪性肝病的新型诊断工具:揭示与已知和潜在疾病生物标志物的关系
Diagnostics (Basel). 2023 Jul 13;13(14):2363. doi: 10.3390/diagnostics13142363.
2
Early prediction of in-hospital death of COVID-19 patients: a machine-learning model based on age, blood analyses, and chest x-ray score.基于年龄、血液分析和胸部 X 光评分的 COVID-19 患者住院期间死亡的早期预测:机器学习模型。
Elife. 2021 Oct 18;10:e70640. doi: 10.7554/eLife.70640.
3

本文引用的文献

1
Magnetic Resonance Imaging for the Pre-Surgical Assessment of Endometrial Cancer: Results in a Routine Clinical Setting, Outside Dedicated Trials; a Cross-sectional Study.
Anticancer Res. 2016 Apr;36(4):1891-4.
2
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
3
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.欧洲肿瘤内科学会(ESMO)-欧洲妇科肿瘤学会(ESGO)-欧洲放射肿瘤学会(ESTRO)子宫内膜癌共识会议:诊断、治疗与随访
HE4 as a Biomarker for Endometrial Cancer.
人附睾蛋白4作为子宫内膜癌的生物标志物
Cancers (Basel). 2021 Sep 23;13(19):4764. doi: 10.3390/cancers13194764.
4
A Conformation Variant of p53 Combined with Machine Learning Identifies Alzheimer Disease in Preclinical and Prodromal Stages.一种与机器学习相结合的p53构象变体可在临床前和前驱阶段识别阿尔茨海默病。
J Pers Med. 2020 Dec 26;11(1):14. doi: 10.3390/jpm11010014.
5
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients.治疗前血清HE4水平作为子宫颈癌患者的新型独立预后生物标志物
Front Oncol. 2020 Sep 29;10:584022. doi: 10.3389/fonc.2020.584022. eCollection 2020.
6
Usefulness of HE4 protein in differentiation of pelvic masses in woman.HE4蛋白在女性盆腔肿块鉴别诊断中的应用价值。
Prz Menopauzalny. 2019 Apr;18(1):27-32. doi: 10.5114/pm.2019.84154. Epub 2019 Apr 9.
7
Comparative Analysis of Hybrid Models for Prediction of BP Reactivity to Crossed Legs.交叉腿时血压反应的混合模型预测的比较分析。
J Healthc Eng. 2017;2017:2187904. doi: 10.1155/2017/2187904. Epub 2017 Nov 26.
Radiother Oncol. 2015 Dec;117(3):559-81. doi: 10.1016/j.radonc.2015.11.013. Epub 2015 Dec 9.
4
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy.HE4用于识别可能需要进行淋巴结切除术的子宫内膜样子宫内膜癌患者的效用。
Adv Med Sci. 2016 Mar;61(1):23-7. doi: 10.1016/j.advms.2015.07.010. Epub 2015 Aug 9.
5
Prognostic value of human epididymis protein 4 in endometrial cancer and its utility for surgical staging.人附睾蛋白4在子宫内膜癌中的预后价值及其在手术分期中的应用
J Obstet Gynaecol Res. 2015 Oct;41(10):1644-52. doi: 10.1111/jog.12764. Epub 2015 Jul 30.
6
Utility of tumor marker HE4 as prognostic factor in endometrial cancer: a single-center controlled study.肿瘤标志物HE4作为子宫内膜癌预后因素的效用:一项单中心对照研究。
Tumour Biol. 2015 Jun;36(6):4151-6. doi: 10.1007/s13277-015-3049-3. Epub 2015 Jan 11.
7
Serum HE4 as a prognostic marker in endometrial cancer--a population based study.血清 HE4 作为子宫内膜癌的预后标志物——一项基于人群的研究。
Gynecol Oncol. 2014 Jan;132(1):159-65. doi: 10.1016/j.ygyno.2013.10.036. Epub 2013 Nov 6.
8
HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET).HE4 和 CA125 水平在子宫内膜癌患者术前评估中的应用:一项前瞻性多中心研究(ENDOMET)。
Acta Obstet Gynecol Scand. 2013 Nov;92(11):1313-22. doi: 10.1111/aogs.12235.
9
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome.人附睾蛋白 4 作为一种血清标志物用于诊断子宫内膜癌和预测临床预后。
Clin Chem Lab Med. 2012 Dec;50(12):2189-98. doi: 10.1515/cclm-2011-0757.
10
HE4 in gynecological cancers: report of a European investigators and experts meeting.HE4 在妇科癌症中的应用:欧洲研究人员和专家会议报告。
Clin Chem Lab Med. 2012 Dec;50(12):2127-36. doi: 10.1515/cclm-2012-0373.